1. Pink Sheet
  2. >>Compliance

Relying On Perfection In An Imperfect World: ADHD Drug Shortage Could Spur Push For DEA Reform

 
• By Sarah Karlin-Smith

Ongoing stimulant shortages leads to calls for DEA to allow for more elasticity in the supply chains of drugs with potential for abuse, but in wake of ongoing opioid crisis agency appears willing to potentially shift but not up quotas. 

US Drug Enforcement Administration flag
The DEA quota system adds extra layers of complication to the ADHD medication shortage • Source: Shutterstock

The ongoing shortage of stimulant medications used to treat ADHD is placing a target on the US Drug Enforcement Administration and its complicated system for allocating quota of controlled substances deemed at high potential for abuse as the tightly regulated process seems to be making it too difficult for manufacturers to adjust to changes in the supply chain.

Key Takeaways

  • ADHD drug shortage situation lacks some of the “typical” shortage characteristics. Sources said the medicines are profitable to make and there are more than a dozen manufacturers.

The ADHD drug shortage doesn’t match the typical characteristics of US drugs in short supply, which are often complex older...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By Sue Sutter

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.